J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morganroth, J
Right arrow Articles by Rosenberg, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morganroth, J
Right arrow Articles by Rosenberg, A
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Lack of effect of azelastine and ketoconazole coadministration on electrocardiographic parameters in healthy volunteers

J Morganroth, WH Lyness, JL Perhach, GG Mather, JE Harr, WF Trager, RH Levy, and A Rosenberg

Azelastine, an antihistamine with additional pharmacologic properties, was evaluated for a possible influence on pharmacokinetic and electrocardiographic parameters due to its coadministration with CYP3A4 inhibitor ketoconazole (200 mg every 12 hrs). Twelve volunteers entered this three-period, open-label study. Electrocardiographic parameters (PR, QRS and QTc intervals and U-wave morphology) were monitored after 14 days of azelastine HCl (4.4 mg every 12 hrs), after 7 days of either azelastine/ketoconazole or azelastine/placebo, and after a 21-day washout period, which was then followed by a 7-day administration of ketoconazole alone. None of the treatments resulted in meaningful alterations of electrocardiographic variables. Pharmacokinetic parameters could not be estimated because ketoconazole metabolites interfered with azelastine assay procedures. In vitro tests with human liver microsomes were used to characterize azelastine's inhibition spectrum. Azelastine did not inhibit CYP3A4 activity but it did inhibit CYP2D6 and CYP2C19 activity with Ki values exceeding maximum plasma concentration by 120 to 800-fold. Therefore, in vitro tests and the absence of electrocardiographic effects suggests azelastine can be safely administered with CYP3A4 inhibitors.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
B. Darpo, M. Agin, D. J. Kazierad, G. Layton, G. Muirhead, P. Gray, and D. K. Jorkasky
Man Versus Machine: Is There an Optimal Method for QT Measurements in Thorough QT Studies?
J. Clin. Pharmacol., June 1, 2006; 46(6): 598 - 612.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Nakajima, S. Nakamura, S. Tokudome, N. Shimada, H. Yamazaki, and T. Yokoi
Azelastine N-Demethylation by Cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in Human Liver Microsomes: Evaluation of Approach to Predict the Contribution of Multiple CYPs
Drug Metab. Dispos., December 1, 1999; 27(12): 1381 - 1391.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
T. Imai, M. Taketani, T. Suzu, K. Kusube, and M. Otagiri
In Vitro Identification of the Human Cytochrome P-450 Enzymes Involved in the N-Demethylation of Azelastine
Drug Metab. Dispos., August 1, 1999; 27(8): 942 - 946.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
M. Nakajima, K. Ohyama, S. Nakamura, N. Shimada, H. Yamazaki, and T. Yokoi
Inhibitory Effects of Azelastine and Its Metabolites on Drug Oxidation Catalyzed by Human Cytochrome P-450 Enzymes
Drug Metab. Dispos., July 1, 1999; 27(7): 792 - 797.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American College of Clinical Pharmacology